证券代码：688277 证券简称：天智航 公告编号：2025-034 北京天智航医疗科技股份有限公司 关于作废 2023 年限制性股票激励计划部分已授予尚未归属 的限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京天智航医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开的第六届董事会第二十二次会议、第五届监事会第十次会议，审议通过了 《关于作废 2023 年限制性股票激励计划部分已授予尚未归属的限制性股票的议 案》。现将有关事项说明如下： 一、本激励计划已履行的相关审批程序 了《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东 大会授权董事会办理公司 2023 年限制性股票激励计划有关事项的议案》等相关 议案。公司独立董事就本次激励计划相关议案发表了独立意见。 的信息在公司内部进行了公示。截至公示期满，公司监事会未收到任何人对本次 拟 激 励 对 象 提 出 的 异 议 。 ...

Core Points - The company announced that the second vesting period of the 2023 restricted stock incentive plan has met the vesting conditions, allowing for the vesting of 3.86466 million shares, which accounts for 0.85% of the company's total share capital [1][10][18] Group 1: Incentive Plan Overview - The total number of restricted stocks to be granted under the incentive plan is not to exceed 8.6875 million shares, with the initial grant accounting for 6.878 million shares (1.53% of total share capital) and the reserved grant accounting for 1.7195 million shares (0.38% of total share capital) [1][2] - The vesting schedule includes two periods: the first vesting period is 24 months after the initial grant, and the second vesting period is 36 months after the initial grant [2][10] Group 2: Performance Assessment Criteria - The performance assessment for the initial grant includes two conditions: a revenue growth rate of at least 90% in 2024 compared to 2022, or obtaining at least two new orthopedic surgical robots' medical device registration licenses during 2023-2024 [3][4] - For the reserved grant, the performance assessment criteria are similar but adjusted for the years 2024-2025, requiring a revenue growth rate of at least 140% in 2025 compared to 2022, or obtaining at least three new orthopedic surgical robots' medical device registration licenses during 2023-2025 [4][5] Group 3: Approval and Compliance - The incentive plan has undergone necessary approvals, including independent opinions from the board and the supervisory committee, confirming compliance with relevant regulations [6][15] - The supervisory committee verified the eligibility of 148 incentive recipients, with 95 from the initial grant and 117 from the reserved grant, confirming that the performance assessment results are compliant and truthful [18][20]

Core Viewpoint - The company announced the repurchase and cancellation of 8,000 restricted stocks from the 2025 incentive plan due to the departure of one incentive object, adjusting the repurchase price to 7.17 yuan per share [1][5][6]. Summary by Sections 1. Approval Process and Disclosure - The company held meetings to approve the repurchase and cancellation of restricted stocks, which included necessary reviews and disclosures [1][2][3]. 2. Reasons and Details for Repurchase - The repurchase is based on the incentive plan's provisions, as the departing employee no longer qualifies for the incentive [3][4]. - The adjusted repurchase price is calculated based on the previous price of 7.29 yuan minus a dividend of 0.12 yuan, resulting in 7.17 yuan per share [4][5]. 3. Financial Impact and Stock Structure - The total amount for the repurchase is 57,360 yuan plus interest, sourced from the company's own funds [5]. - Post-repurchase, the total share capital will decrease from 183,038,400 shares to 183,030,400 shares, with no change in the actual control of the company [5][6]. 4. Opinions from Committees - The Board's Compensation and Assessment Committee and the Supervisory Committee both agree that the repurchase and price adjustment comply with relevant regulations and will not harm shareholder interests [6][7]. 5. Legal Opinion - The legal opinion confirms that the repurchase and adjustments have received necessary authorizations and comply with applicable laws and regulations [7][8].

Core Viewpoint - The legal opinion letter from Beijing Jiayuan Law Firm confirms the legality and compliance of Hefei Xueqi Electric Co., Ltd.'s plan to repurchase and cancel part of the restricted stocks under the 2025 incentive plan, as well as the adjustment of the repurchase price [1][5][8] Summary by Relevant Sections Approval and Authorization of Repurchase and Adjustment - The 2025 incentive plan has undergone necessary procedures and was approved by the company's board of directors [3][4] - The board has authorized the repurchase of 8,000 shares of restricted stock from a departing incentive object and adjusted the repurchase price to 7.17 yuan per share [4][5] Specifics of the Repurchase and Adjustment - The repurchase is due to one incentive object leaving the company, which triggers the cancellation of their unvested restricted stocks [6][8] - The adjustment of the repurchase price is based on the company's profit distribution plan, which included a cash dividend of 1.2 yuan per 10 shares [6][7] Conclusion - The necessary approvals and authorizations for the repurchase and adjustment have been obtained, and the actions comply with relevant regulations [5][8] - The company must still obtain shareholder approval and fulfill disclosure obligations regarding the repurchase [8]

证券代码：301123 证券简称：奕东电子 公告编码：2025-050 奕东电子科技股份有限公司 关于向公司2025年限制性股票激励计划激励对象 授予限制性股票的公告 特别提示: 票 22.50 万股 均为 13.55 元/股 奕东电子科技股份有限公司（以下简称"公司"）2025年限制性股票激励计划 （以下简称"本激励计划"、"本次激励计划"或"《激励计划》"）规定的限制 性股票授予条件已经成就，根据公司2025年第一次临时股东会的授权，公司于 会议，审议通过了《关于向激励对象授予限制性股票的议案》，确认同意以2025 年8月27日为授予日，向5名激励对象授予104.00万股第一类限制性股票，授予价 格为13.55元/股；向10名激励对象授予22.50万股第二类限制性股票，授予价格为 一、本次激励计划简述 公司于 2025 年 8 月 19 日召开了 2025 年第一次临时股东会，会议审议通过 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 了《关于 <奕东电子科技股份有限公司 ensp="ensp" 年限制性股票激励计划="年限制性股票激励计划" 草 案=" ...

Core Viewpoint - The company plans to repurchase and cancel a total of 481,978 restricted stocks from its 2024 incentive plan due to the disqualification of seven incentive targets who have left or retired from the company [1][2][10]. Summary by Sections Reasons for Repurchase - The repurchase is due to seven individuals no longer meeting the criteria for incentive targets, with two leaving voluntarily, two having their contracts terminated by mutual agreement, and three retiring [2][7][10]. Quantity and Nature of Stocks - The total number of restricted stocks to be repurchased is 481,978 shares, which will reduce the company's total share capital from 778,991,206 shares to 778,509,228 shares [1][10]. Impact on Company - After the completion of the repurchase, the structure of the company's shares will change, with limited shares decreasing from 8,003,256 to 7,521,278, while unlimited shares remain unchanged at 770,987,950 [10]. Approval Process - The repurchase proposal was approved by the Compensation and Assessment Committee and the Board of Directors, with unanimous votes in favor during meetings held on August 27, 2025 [11].

Core Insights - Fortior (01304) reported a mid-year performance for 2025, with revenue approximately 375 million, representing a year-on-year increase of 32.8% [1] - Gross profit was around 195 million, showing a year-on-year growth of 31.1% [1] - Net profit stood at 116.5 million, reflecting a year-on-year decline of 4.5%, with basic earnings per share at 1.26 [1] - The decrease in net profit was primarily due to the implementation of a restricted stock incentive plan in November 2024, which led to an increase in share-based payment expenses by approximately 32 million year-on-year; excluding this factor, the group's profit would have increased by 18.7% year-on-year [1] Financial Performance - Revenue: Approximately 375 million, up 32.8% year-on-year [1] - Gross Profit: Approximately 195 million, up 31.1% year-on-year [1] - Net Profit: 116.5 million, down 4.5% year-on-year [1] - Basic Earnings Per Share: 1.26 [1] Incentive Plan Impact - The restricted stock incentive plan implemented in November 2024 resulted in an increase of share-based payment expenses by approximately 32 million year-on-year [1] - Adjusted for this expense, the group's profit would have shown an increase of 18.7% year-on-year [1]

Core Points - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. held its 23rd meeting of the second board of directors on August 26, 2025, with all 9 directors present, ensuring compliance with legal and regulatory requirements [1] - The board approved several key proposals, including the review of the 2025 semi-annual report and the special report on the use of raised funds [2][3] - The board also approved the cancellation of the supervisory board and amendments to the company's articles of association, which will be submitted for shareholder approval [2][3] - The board nominated candidates for the third board of directors, including both non-independent and independent directors, pending shareholder approval [3][4] - The board reviewed and approved the semi-annual evaluation report of the 2025 quality improvement and efficiency recovery action plan [4] - The board discussed the 2025 restricted stock incentive plan and its management methods, which will also require shareholder approval [5][6] - The board proposed to authorize the board to handle matters related to the 2025 employee stock ownership plan, pending shareholder approval [8][9]

Meeting Overview - The second meeting of the Supervisory Board of Chengdu XianDao Pharmaceutical Development Co., Ltd. was held on August 26, 2025, with all three supervisors present [1] - The meeting was convened in accordance with relevant laws and regulations, and the resolutions passed were deemed legal and effective [1] Resolutions Passed - The Supervisory Board approved the company's 2025 semi-annual report and its summary [2] - The board also approved the special report on the storage and actual use of the raised funds for the first half of 2025 [2] - A resolution was passed to cancel the Supervisory Board, amend the company’s articles of association, and remove the chairman of the Supervisory Board, pending approval from the shareholders' meeting [2][3] - The board approved the draft of the 2025 restricted stock incentive plan and its summary, which will also be submitted for shareholder approval [3] - The implementation assessment management measures for the 2025 restricted stock incentive plan were approved, pending shareholder approval [3] - The verification of the list of incentive objects for the 2025 restricted stock incentive plan was also approved [3] - The draft of the 2025 employee stock ownership plan and its summary could not be resolved due to two supervisors abstaining from voting, and it will be submitted for shareholder approval [4] - The management measures for the 2025 employee stock ownership plan could not be resolved for the same reason and will also be submitted for shareholder approval [4]

Core Viewpoint - The Shenzhen BGI Genomics Co., Ltd. is holding its third extraordinary general meeting of shareholders in 2025 to discuss and vote on several key proposals, including amendments to the 2024 restricted stock incentive plan and the employee stock ownership plan, aimed at enhancing employee motivation and aligning interests with shareholders [5][22]. Group 1: Meeting Procedures - The meeting will ensure the legal rights of all shareholders and maintain order and efficiency, following relevant laws and regulations [1][2]. - Attendees must register and confirm their participation before the meeting starts, as latecomers will not be allowed to vote [2][3]. - The meeting will follow a predetermined agenda, allowing shareholders to exercise their rights to speak, inquire, and vote [2][3][4]. Group 2: Proposals and Amendments - Proposal One involves the revision of the 2024 restricted stock incentive plan, which aims to enhance performance assessment indicators at the company level [7][9]. - The revision is driven by the need to adapt to external market changes and to focus on increasing market share in the gene sequencing equipment sector, which is crucial for future revenue growth [9][10]. - Proposal Two addresses the amendments to the 2024 employee stock ownership plan, which also includes new performance assessment indicators to improve governance and employee engagement [16][17]. Group 3: Performance Assessment Criteria - The performance assessment for the incentive plans will be based on revenue growth rates, excluding impacts from public health events, with specific targets set for 2024 and 2025 [9][19]. - The revised criteria will include metrics related to gene sequencing equipment sales, emphasizing the importance of capturing market share to secure long-term customer value [10][18]. - The company aims to ensure that the revised performance targets remain challenging yet achievable, fostering a sustainable growth environment [20][21].